Free tool
FAERS Monitor: Ilumya
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761067 or its brand name (Ilumya, Tildrakizumab-Asmn). Reports on generic versions are filed under their own applications.
Reports
2,410
Serious
540
22% of reports
Hospitalization
94
Death reported
174
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue489
- drug ineffective313
- intentional dose omission215
- death167
- condition aggravated121
- psoriasis109
- off label use96
- self-medication92
- pruritus89
- inappropriate schedule of product administration86
- therapy cessation85
- product storage error84
- rash81
- diarrhoea47
- therapy interrupted43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 83 |
| 2020 | 127 |
| 2021 | 168 |
| 2022 | 217 |
| 2023 | 154 |
| 2024 | 339 |
| 2025 | 591 |
| 2026 | 730 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,749 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| self-medicationSignal | 92 | 199.8 | 163.1 | 17,602 |
| intentional dose omissionSignal | 215 | 66.3 | 58.3 | 13,679 |
| product dose omission issueSignal | 489 | 14.5 | 13.4 | 6,227 |
| therapy cessationSignal | 85 | 14.5 | 11.7 | 1,054 |
| product storage errorSignal | 84 | 8.4 | 6.8 | 540 |
| psoriasisSignal | 109 | 7.3 | 6.1 | 588 |
| therapy interruptedSignal | 43 | 5.3 | 3.9 | 144 |
| inappropriate schedule of product administrationSignal | 86 | 4.2 | 3.4 | 205 |
| condition aggravatedSignal | 121 | 3.5 | 2.9 | 214 |
| drug ineffectiveSignal | 313 | 2.1 | 1.9 | 184 |
| pruritusSignal | 89 | 2.0 | 1.6 | 46 |
| death | 167 | 1.7 | 1.5 | 49 |
| rash | 81 | 1.6 | 1.3 | 19 |
| off label use | 96 | 1.0 | 0.8 | 0 |
| diarrhoea | 47 | 0.6 | 0.5 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.